Muscular Dystrophy Clinical Trials

Program_Formal_v6.14.formal1  

Acne usually begins in the teenage years and disappears after eight to 10 years. In some cases, it can persist until the 30s and even 40s. Acne is caused by inflammation of the hair follicles. It most commonly affects the face, back and chest. Features include blackheads, whiteheads, pimples (zits) …

VAXX-Formal-Program 1 & 2  

Test

Test prescreener translations ( DO NOT TOUCH)  

translations

UAT Program -BLL  

Individualizing Treatment for Asthma in Primary Care (Full Study) (iTREAT-PC)

While asthma therapy is becoming more individualized based on asthma phenotypes, more research is needed to tailor newer therapies to individuals. Inhaled corticosteroid (ICS) medications are the foundation of care for all individuals with persistent asthma. But ICS use is not without possible long term side effects.This study will compare …

Safety and Efficacy of CD19 CAR-T Therapy for Recurrent/Refractory Autoimmune Diseases

This study is a single center, open label exploratory clinical trial aimed at evaluating the safety and efficacy of universal CD19 CAR-T therapy in subjects with autoimmune diseases.The study will adopt the traditional dose escalation model "3+3" design, setting up three dose groups with a starting dose of 0.5 × …

Diffusion MRI for Head and Neck Cancer  

The proposed study is to investigate the feasibility of using quantitative diffusion MRI (dMRI) methods for accurate and comprehensive assessment of treatment response. dMRI is a powerful tool to probe treatment-induced change in tumors. It is a unique in vivo imaging technique sensitive to cellular microstructures at the scale of …

AutoRun151

AutomationRun151

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with relapsed or refractory multiple myeloma (RRMM).

Elranatamab in R/R Multiple Myeloma

This research is being done to see if the study drug, elranatamab, reduces the risk of disease progression (worsening disease) after idecabtagene vicleucel in relapsed refractory multiple myeloma.